ANGELINI, GIUSEPPE
ANGELINI, GIUSEPPE
Dipartimento di Bioscienze
Development of a high-throughput screening assay to identify Nfix-modulating drugs as a novel therapy for muscular dystrophy
2025 G. Rovetta, C. Monzani, G. Angelini, L. Bertazzoli, S. Di Savino, R. Epis, G. Careccia, G. Ferrari, C. Bonfanti, D. Dolfini, G. Messina
MEK-inhibitors decrease Nfix in muscular dystrophy but induce unexpected calcifications, partially rescued with Cyanidin diet
2024 G. Angelini, E. Capra, F. Rossi, G. Mura, M. Saclier, V. Taglietti, G. Rovetta, R. Epis, G. Careccia, C. Bonfanti, G. Messina
Therapeutic approaches to preserve the musculature in Duchenne Muscular Dystrophy: The importance of the secondary therapies
2022 G. Angelini, G. Mura, G. Messina
Selective ablation of Nfix in macrophages attenuates muscular dystrophy by inhibiting fibro‐adipogenic progenitor‐dependent fibrosis
2022 M. Saclier, G. Angelini, C. Bonfanti, G. Mura, G. Temponi, G. Messina
DRUG-MEDIATED NFIX INHIBITION AS A NEW THERAPY FOR MUSCULAR DYSTROPHIES
2021 G. Angelini
Nutritional intervention with cyanidin hinders the progression of muscular dystrophy
2020 M. Saclier, C. Bonfanti, S. Antonini, G. Angelini, G. Mura, F. Zanaglio, V. Taglietti, V. Romanello, M. Sandri, C. Tonelli, K. Petroni, M. Cassano, G. Messina
RhoA and ERK signalling regulate the expression of the transcription factor Nfix in myogenic cells
2018 V. Taglietti, G. Angelini, G. Mura, C. Bonfanti, E. Caruso, S. Monteverde, G. Le Carrou, S. Tajbakhsh, F. Relaix, G. Messina